刘明,李永奇,李凯,刘志强.替罗非班用于治疗颅内动脉瘤栓塞期间的血栓栓塞的临床疗效观察.[J].中南医学科学杂志.,2019,(5):527-530.
替罗非班用于治疗颅内动脉瘤栓塞期间的血栓栓塞的临床疗效观察
Clinical efficacy and safety of tirofiban in the treatment of thromboembolism during intracranial aneurysm embolization
投稿时间:2018-11-16  修订日期:2019-04-18
DOI:10.15972/j.cnki.43-1509/r.2019.05.021
中文关键词:  替罗非班  动脉瘤  血栓栓塞  安全性  再通
英文关键词:tirofiban  aneurysm  thromboembolism  safety  recanalization
基金项目:
作者单位
刘明 皖北煤电集团总医院神经外科,安徽 宿州 233004 
李永奇 皖北煤电集团总医院神经外科,安徽 宿州 233004 
李凯 皖北煤电集团总医院神经外科,安徽 宿州 233004 
刘志强 皖北煤电集团总医院神经外科,安徽 宿州 233004 
摘要点击次数: 445
全文下载次数: 467
中文摘要:
      旨在评价替罗非班用于治疗颅内动脉瘤血栓栓塞的临床疗效和安全性。选取289例经颅内动脉瘤采用微弹簧圈栓塞治疗后发生血栓栓塞76个患者,其中48个进行替罗非班治疗和28个阿司匹林治疗。结果显示,与阿司匹林治疗患者比较,用药治疗1天、3个月、6个月,替罗非班用药患者血栓栓塞完全或部分溶解率显著增高,分别为(10.71% vs 66.67%),(21.43% vs 83.33%),(55.56% vs 95.83%)。结果表明,替罗非班能有效地解决血栓栓塞症,并且具有较高的安全性和再通率。
英文摘要:
      To evaluate the clinical efficacy and safety of tirofiban in the treatment of thromboembolism, 76 cases of thromboembolism found in 289 cases of intracranial aneurysms whom were treated with microcoil embolization were treated with tirofiban(48 cases) and aspirin (28 cases). Results show, compared to the aspirin treatment group, the rate of thromboembolism completely or partially dissolved in the tirofiban treatment group at the day 1,3 months, 6 months follow-up were significant increased(10.71% vs 66.67%),(21.43% vs 83.33%),(55.56% vs 95.83%), respectively. These results indicate that tirofiban can effectively resolve thromboembolism,and has a high safety and recanalization rate.
查看全文  查看/发表评论  下载PDF阅读器
关闭
function PdfOpen(url){ var win="toolbar=no,location=no,directories=no,status=yes,menubar=yes,scrollbars=yes,resizable=yes"; window.open(url,"",win); } function openWin(url,w,h){ var win="toolbar=no,location=no,directories=no,status=no,menubar=no,scrollbars=yes,resizable=no,width=" + w + ",height=" + h; controlWindow=window.open(url,"",win); } &et=3C06DB566315F8DC78C14CE21C0BF806B69C0C8A723229A4B427A127DD327CFFFB3A980EBE0FFBC4ED76EA29D266516BAB369D70F9C19176D762235A93A996871430A7EBCDBB8B2D492184DC64D628EFEDDB69A9F11CF2B4C716C9A9D7E578617DD59386F8F6DD961CA487E3BC072355FABDC73CA197E3D4&pcid=A9DB1C13C87CE289EA38239A9433C9DC&cid=BB33F1C95224820A&jid=6A20DF2A798996E24F064D5ECF83A153&yid=B6351343F4791CA3&aid=7BA62EAAEF4CF3CAB6F3D510D4249DBE&vid=&iid=94C357A881DFC066&sid=F3549E0657848E2A&eid=BB98BB04E861B6F5&fileno=20190521&flag=1&is_more=0">